A Phase 1 interventional study of YM443 and Placebo in Functional Dyspepsia, sponsored by Astellas Pharma Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-24.
Sponsored by Astellas Pharma Inc · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.
Among the 11 studies testing Z 338 in Dyspepsia, this one is the 8th largest by enrollment, is the only one that started in 2009, is the only one in phase 1, and was the 8th registered.
372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.
Browse Dyspepsia studies →1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:
Aga Khan University
Ages 18–70
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2009.
This study's enrollment of 80 is below the median of 89 across 302 interventional studies indexed under Dyspepsia.
Median enrollment 282 across the 11 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 3 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
Astellas Pharma Inc has 3 studies filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
1 of the studies testing Z 338 in Dyspepsia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449689Aga Khan UniversityComparing Acotiamide and Itopride for the Management of Indigestion | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing Z 338 in Dyspepsia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates whether YM443 causes any changes in the electrocardiogram of healthy adults.
Each subject participates in all four treatment periods separated by washout periods.
In order to maintain the blind between arms, all subjects will receive the same number of tablets per day in each period of either active drug or placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: YM443
Drug: YM443
Drug: Moxifloxacin
Oral
Also known as: Z-338, acotiamide hydrochloride
Oral
Oral
Also known as: Avelox
Mean change in the QTcF (Fridericia's correction) between each active treatment and placebo
Time frame: Following four days of dosing
The mean change of the QTcI (Individual correction) and QTcB (Bazett's correction) between each active treatment and placebo.
Time frame: Following four days of dosing
The pharmacokinetics of YM443 in these subjects
Time frame: Day 5
The safety and tolerability of YM443
Time frame: Following four days of dosing
The record gives a start of Feb 2009, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Z 338